ClinicalTrials.gg
RecruitingNCT05447559CALIPSOUpdated Mar 25, 2026

Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study

A Phase 4 interventional study of Cefazolin and Water for injection in Surgical Site Infection, sponsored by Monash University. Recruiting at 27 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Monash University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
9,180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing cefazolin in Surgical Wound Infection — 4 open to participants now, 5 under way, 2 of them phase 3. Cefazolin · Surgical Wound Infection.

Planned enrollment
2nd of 18
9,180 · median 180
Started
2023
with 1 other
Phase 4
8 of 18
3 open now
Registered
11th of 18
by date
Lead sponsor
1 of 18
Monash University

Among the 18 studies testing cefazolin in Surgical Wound Infection, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2023, is one of 8 in phase 4, and was the 11th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

4 of the 18 studies testing cefazolin in Surgical Wound Infection are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cefazolin

Cefazolin: first FDA approval 1973 (ANCEF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing cefazolin in Surgical Wound Infection, or all of them as a file.
02

Study summary

This multicentre, adaptive, pragmatic, double-blind, three-arm, placebo-controlled, randomised, non-inferiority clinical trial will compare the incidence of surgical site infection and other healthcare associated infections, health economic and microbiological impact after intraoperative only (Arm A), to 24 hours (Arm B) and, to 48 hours (Arm C) of IV cefazolin and placebo postoperative surgical antimicrobial prophylaxis in patients undergoing cardiac surgery

Read the detailed description

This trial will evaluate the clinical effectiveness, health-economic outcomes and microbiological impact of intraoperative (only) compared with intraoperative plus postoperative prophylaxis durations in patients undergoing cardiac surgery.

CALIPSO, a multicentre, adaptive, double-blind, three-arm, placebo-controlled, phase IV, noninferiority trial will examine the incidence proportion of SSI following cardiac surgery. Our three-intervention trial will compare:

Arm A Administration of prophylaxis in intraoperative period only Arm B Administration of prophylaxis in intraoperative plus for 24 hours postoperatively Arm C Administration of prophylaxis in intraoperative plus for 48 hours postoperatively

03

Conditions studied

  • Surgical Site Infection

Keywords

  • Cardiac surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Adult patients undergoing cardiac surgery involving a median sternotomy

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • American Society of Anesthesiology (ASA) 5
  • Subjects with \<40mL/min/1.73m2 or those requiring continuous renal replacement therapy, haemodialysis or peritoneal dialysis
  • Surgery for suspected or proven endocarditis or deep sternal wound infection
  • Documented cefazolin
  • Documented methicillin resistant Staphylococcus aureus (MRSA) colonisation or infection in the 12-months prior to index surgery
  • Cardiac transplantation
  • Procedures involving insertion ventricular assist device or mechanical circulatory support device
  • Procedures not involving a median sternotomy
  • Patients previously enrolled and randomised to the CALIPSO trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
9,180 participants (estimated)

Study arms

  • Placebo comparator
    Intraoperative only Surgical Antimicrobial Prophylaxis Arm

    Placebo administered every 8-hours following the preoperative dose (time=0) for a total of five postoperative doses

    Drug: Water for injection

  • Other
    Intraoperative and 24-hours Postoperative Surgical Antimicrobial Prophylaxis Arm

    Cefazolin (2g) administered 8-hourly following the preoperative dose (time=0) for two doses then placebo 8-hourly for three doses (total of 5 postoperative doses of cefazolin/placebo)

    Drug: Cefazolin · Drug: Water for injection

  • Active comparator
    Intraoperative and 48-hours Postoperative Surgical Antimicrobial Prophylaxis Arm

    Cefazolin (2g) administered every 8-hours following the preoperative dose (time=0) for a total of five postoperative doses

    Drug: Cefazolin

Interventions

  • Intravenous administration of 2 g cefazolin

  • DrugWaterStudies of WaterWater pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous administration of 10mL sterile water for injection

06

What researchers measure

Primary outcomes

  1. Incidence of surgical site infection

    Surgical site infection according to CDC / NHSN definition

    Time frame: 90 days from index surgery

Secondary outcomes

  1. Incidence of Clostridioides difficile infection

    Clostridioides difficile infection according the CDC definitions

    Time frame: 30 days from index surgery

  2. Incidence of other health care association infections

    Composite of all other HCAIs (pneumonia, blood stream infection and urinary tract infection)

    Time frame: From date of randomization until the date of discharge from the acute healthcare facility or date of death from any cause, whichever came first, assessed up to 30 days from index surgery

Other outcomes

  1. Incidence of Antimicrobial hypersensitivity reactions

    Immediate (\<48 hrs after exposure) or delayed (≥24 hrs after exposure) reaction to study drug

    Time frame: From date of randomization until the date of discharge from the acute healthcare facility or date of death from any cause, whichever came first, assessed up to 30 days from index surgery

  2. All-cause mortality rate

    Death reported up to 180 days from index cardiac surgery due to any cause.

    Time frame: 180 days from index surgery

  3. Incidence of acute kidney injury

    AKI will be defined according to the RIFLE criteria

    Time frame: From date of randomization until the date of discharge from the acute healthcare facility or date of death from any cause, whichever came first, assessed up to 30 days from index surgery

  4. Incidence of surgical site infections due to drug-resistant infections

    Surgical site infections due to drug-resistant infections (defined as resistance to cefazolin)

    Time frame: 90 days from index surgery

07

Study locations

21 of 27 sites recruiting
08

References and documents

Publications

  • Peel T, McGiffin D, Smith J, Forbes A, Marasco S, Pilcher D, Stewardson AJ, Petrie D, Peleg AY, Wisniewski J, Forster S, Druce P, Roney J, Astbury S, Berkovic D, Mccracken P, Myles PS; CALIPSO Trial Steering Committee. Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol. BMJ Open. 2026 Mar 18;16(3):e115209. doi: 10.1136/bmjopen-2025-115209. PubMed 41857861 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 58 months after the start.

Of 45 non-industry phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 58 months is above that.

Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2022
First posted
Jul 7, 2022
StartActual
Feb 7, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05447559
Lead sponsor
Monash University
Collaborators
ANZCA CTN
Responsible party
Trisha Nicole Peel (Professor Trisha Peel, Monash University) — Principal investigator
First posted
Jul 7, 2022
Start date
Feb 7, 2023
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Mar 25, 2026

Study contacts

Paige Druce, MSc(Epi)
Contact
paige.druce@monash.edu
9903 0016 ext. +61 3
Sarah Astbury
Contact
sarah.astbury@monash.edu
9076 6071 ext. +61 3
Trisha Peel, MBBS GradCertRes FRACP PhD
principal investigator · Monash University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cefazolin

Start the discussion